Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.
Gomez EB, Ebata K, Randeria HS, Rosendahl MS, Cedervall EP, Morales TH, Hanson LM, Brown NE, Gong X, Stephens J, Wu W, Lippincott I, Ku KS, Walgren RA, Abada PB, Ballard JA, Allerston CK, Brandhuber BJ. Gomez EB, et al. Among authors: gong x. Blood. 2023 Jul 6;142(1):62-72. doi: 10.1182/blood.2022018674. Blood. 2023. PMID: 36796019 Free PMC article.
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.
Litchfield LM, Boehnke K, Brahmachary M, Mur C, Bi C, Stephens JR, Sauder JM, Gutiérrez SM, McNulty AM, Ye XS, Wu W, Lallena MJ, Gong X, Merzoug FF, Jansen VM, Buchanan SG. Litchfield LM, et al. Among authors: gong x. Oncotarget. 2020 Apr 28;11(17):1478-1492. doi: 10.18632/oncotarget.27539. eCollection 2020 Apr 28. Oncotarget. 2020. PMID: 32391118 Free PMC article.
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer.
Torres-Guzmán R, Calsina B, Hermoso A, Baquero C, Alvarez B, Amat J, McNulty AM, Gong X, Boehnke K, Du J, de Dios A, Beckmann RP, Buchanan S, Lallena MJ. Torres-Guzmán R, et al. Among authors: gong x. Oncotarget. 2017 May 10;8(41):69493-69507. doi: 10.18632/oncotarget.17778. eCollection 2017 Sep 19. Oncotarget. 2017. PMID: 29050219 Free PMC article.
Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration.
Zhao G, Green CF, Hui YH, Prieto L, Shepard R, Dong S, Wang T, Tan B, Gong X, Kays L, Johnson RL, Wu W, Bhattachar S, Del Prado M, Gillig JR, Fernandez MC, Roth KD, Buchanan S, Kuo MS, Geeganage S, Burkholder TP. Zhao G, et al. Among authors: gong x. Mol Cancer Ther. 2017 Dec;16(12):2677-2688. doi: 10.1158/1535-7163.MCT-16-0674. Epub 2017 Oct 20. Mol Cancer Ther. 2017. PMID: 29054982
Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
Dowless M, Lowery CD, Shackleford T, Renschler M, Stephens J, Flack R, Blosser W, Gupta S, Stewart J, Webster Y, Dempsey J, VanWye AB, Ebert P, Iversen P, Olsen JB, Gong X, Buchanan S, Houghton P, Stancato L. Dowless M, et al. Among authors: gong x. Clin Cancer Res. 2018 Dec 1;24(23):6028-6039. doi: 10.1158/1078-0432.CCR-18-1256. Epub 2018 Aug 21. Clin Cancer Res. 2018. PMID: 30131386 Free PMC article.
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.
Du J, Yan L, Torres R, Gong X, Bian H, Marugán C, Boehnke K, Baquero C, Hui YH, Chapman SC, Yang Y, Zeng Y, Bogner SM, Foreman RT, Capen A, Donoho GP, Van Horn RD, Barnard DS, Dempsey JA, Beckmann RP, Marshall MS, Chio LC, Qian Y, Webster YW, Aggarwal A, Chu S, Bhattachar S, Stancato LF, Dowless MS, Iversen PW, Manro JR, Walgren JL, Halstead BW, Dieter MZ, Martinez R, Bhagwat SV, Kreklau EL, Lallena MJ, Ye XS, Patel BKR, Reinhard C, Plowman GD, Barda DA, Henry JR, Buchanan SG, Campbell RM. Du J, et al. Among authors: gong x. Mol Cancer Ther. 2019 Dec;18(12):2207-2219. doi: 10.1158/1535-7163.MCT-18-0529. Epub 2019 Sep 17. Mol Cancer Ther. 2019. PMID: 31530649
A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib.
Blosser WD, Dempsey JA, McNulty AM, Rao X, Ebert PJ, Lowery CD, Iversen PW, Webster YW, Donoho GP, Gong X, Merzoug FF, Buchanan S, Boehnke K, Yu C, You XT, Beckmann RP, Wu W, McNeely SC, Lin AB, Martinez R. Blosser WD, et al. Among authors: gong x. Oncotarget. 2020 Jan 21;11(3):216-236. doi: 10.18632/oncotarget.27400. eCollection 2020 Jan 21. Oncotarget. 2020. PMID: 32076484 Free PMC article.
Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1.
Li Y, Mahadevan NR, Duplaquet L, Hong D, Durmaz YT, Jones KL, Cho H, Morrow M, Protti A, Poitras MJ, Springer BF, Bronson RT, Gong X, Hui YH, Du J, Southard J, Thai T, Li S, Lizotte PH, Gokhale PC, Nguyen QD, Oser MG. Li Y, et al. Among authors: gong x. Cell Rep Med. 2023 Nov 21;4(11):101282. doi: 10.1016/j.xcrm.2023.101282. Cell Rep Med. 2023. PMID: 37992688 Free PMC article.
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.
Gong X, Du J, Parsons SH, Merzoug FF, Webster Y, Iversen PW, Chio LC, Van Horn RD, Lin X, Blosser W, Han B, Jin S, Yao S, Bian H, Ficklin C, Fan L, Kapoor A, Antonysamy S, Mc Nulty AM, Froning K, Manglicmot D, Pustilnik A, Weichert K, Wasserman SR, Dowless M, Marugán C, Baquero C, Lallena MJ, Eastman SW, Hui YH, Dieter MZ, Doman T, Chu S, Qian HR, Ye XS, Barda DA, Plowman GD, Reinhard C, Campbell RM, Henry JR, Buchanan SG. Gong X, et al. Cancer Discov. 2019 Feb;9(2):248-263. doi: 10.1158/2159-8290.CD-18-0469. Epub 2018 Oct 29. Cancer Discov. 2019. PMID: 30373917
7,296 results